Endpoints News Announces the 11 Most Promising Biotech Startups of 2022
Rome Therapeutics has been named to the Endpoints 11 list of most promising biotech startups of 2022
Active portfolio
Active portfolio in the news
- Sep 12
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program
Keros Therapeutics presented clinical data from the Part 2 multiple ascending dose portion of its Phase 1 clinical trial of KER-012
- Sep 12
Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study
During three months of treatment with AZP-3601, mean serum calcium levels were maintained within the target range and allowed for the discon
- Sep 12
Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022
Scorpion Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies
- Sep 8
Photys Therapeutics Debuts with $75 Million Series A Funding
Photys Therapeutics debuts with $75 Million Series A to advance new class of bifunctional molecules for precision phosphorylation
- Sep 7
Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
Garuda Therapeutics (Garuda) today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer.
- Jul 21
In Quest for Liver Disease Gene Therapy Vertex Invests $340M in Verve
Massachusetts-based biopharma companies Vertex and Verve Therapeutics entered into exclusive four-year research partnership
- Jun 9
Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin
Funded by grant from Bill & Melinda Gates Foundation, Lyndra answers WHO’s call to investigate ivermectin as malaria eradication strategy.
- Jun 1
Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601
Amolyt Pharma announces positive results from clinical proof of concept trial of AZP-3601, which is being developed as a potential treatment
- May 18
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies
SwanBio Therapeutics announced the completion of a $56M Series B financing round, led by Syncona Limited and Mass General Brigham Ventures
- Mar 17
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601
Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022
- Mar 15
Garuda Therapeutics Announces Appointment of James Desiderio as Chief Regulatory Officer
Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, announces appointment of James Desiderio, Ph.D. as
- Mar 8
Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, MD, to Board
Affinia Therapeutics, an innovative gene therapy company, announced the appointment of Diana M. Brainard, M.D., to its board of directors.
- Mar 1
Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601
Top-line data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022
- Jan 13
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel
Scorpion Therapeutics announced a collaboration with AstraZeneca to discover, develop and commercialize precision medicines against
- Jan 5
Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs
Nine months after Affinia Therapeutics raised $110 million in a Series B, the biotech has set its eyes on the Nasdaq.
- Jan 5
Scorpion Therapeutics Receives BioSpace NextGen Bio “Class of 2022” Recognition
Scorpion Therapeutics, Inc., a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0
- Sep 23, 2021
Garuda thinks it has cracked the code to off-the-shelf stem cell transplants—and investors are betti
We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible....
- Sep 16, 2021
Amolyt Pharma Announces $80 Million Series B Financing
Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners Funds to be used to continue...
- Sep 15, 2021
Simon Sturge Joins Mediar Therapeutics as Executive Chairman
Life sciences leader to advance Mediar’s novel platform for fibrosis